Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors

Kelly L. Schoenbeck; Ehab Atallah; Li Lin; Kevin P. Weinfurt; Jorge Cortes; Michael W.N. Deininger; Vamsi Kota; Richard A. Larson; Michael J. Mauro; Vivian G. Oehler; Javier Pinilla-Ibarz; Jerald P. Radich; Charles A. Schiffer; Neil P. Shah; Richard T. Silver; James E. Thompson; Kathryn E. Flynn

doi:10.1093/jnci/djab184

Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors

Kelly L. Schoenbeck, Ehab Atallah, Li Lin, Kevin P. Weinfurt, Jorge Cortes, Michael W.N. Deininger, Vamsi Kota, Richard A. Larson, Michael J. Mauro, Vivian G. Oehler, Javier Pinilla-Ibarz, Jerald P. Radich, Charles A. Schiffer, Neil P. Shah, Richard T. Silver, James E. Thompson, Kathryn E. Flynn

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Treatment-free remission (TFR) is a goal for patients with chronic myeloid leukemia (CML). Functional outcomes after discontinuing tyrosine kinase inhibitor (TKI) treatment have not been described. Patient-Reported Outcomes Measurement Information System (PROMIS) measures of social, physical, cognitive, and sexual function were assessed over 36 months in 172 adult patients with chronic phase CML from 14 sites at baseline (on TKI) and after discontinuation. Linear mixed-effects models described the average trajectories for each patient-reported outcome measure after discontinuation and in those who restarted TKI. Of 112 patients in TFR at 12 months, 103 (92.0%) had a 3-point or greater improvement in social function, 80 (71.4%) in social isolation, 11 (9.8%) in satisfaction with sex life, 4 (3.6%) in physical function, and no patients had a 3-point or greater improvement in cognitive function or interest in sexual activity. Patients' scores worsened after restarting TKI. This novel information on functional outcomes in TFR can help guide patient and clinician decision making.

Original language	English (US)
Pages (from-to)	160-164
Number of pages	5
Journal	Journal of the National Cancer Institute
Volume	114
Issue number	1
DOIs	https://doi.org/10.1093/jnci/djab184
State	Published - Jan 1 2022

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jnci/djab184

Cite this

Schoenbeck, K. L., Atallah, E., Lin, L., Weinfurt, K. P., Cortes, J., Deininger, M. W. N., Kota, V., Larson, R. A., Mauro, M. J., Oehler, V. G., Pinilla-Ibarz, J., Radich, J. P., Schiffer, C. A., Shah, N. P., Silver, R. T., Thompson, J. E., & Flynn, K. E. (2022). Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors. Journal of the National Cancer Institute, 114(1), 160-164. https://doi.org/10.1093/jnci/djab184

Schoenbeck, KL, Atallah, E, Lin, L, Weinfurt, KP, Cortes, J, Deininger, MWN, Kota, V, Larson, RA, Mauro, MJ, Oehler, VG, Pinilla-Ibarz, J, Radich, JP, Schiffer, CA, Shah, NP, Silver, RT, Thompson, JE & Flynn, KE 2022, 'Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors', Journal of the National Cancer Institute, vol. 114, no. 1, pp. 160-164. https://doi.org/10.1093/jnci/djab184

@article{c02a60ea61c843bb91897e176e6c8940,

title = "Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors",

abstract = "Treatment-free remission (TFR) is a goal for patients with chronic myeloid leukemia (CML). Functional outcomes after discontinuing tyrosine kinase inhibitor (TKI) treatment have not been described. Patient-Reported Outcomes Measurement Information System (PROMIS) measures of social, physical, cognitive, and sexual function were assessed over 36 months in 172 adult patients with chronic phase CML from 14 sites at baseline (on TKI) and after discontinuation. Linear mixed-effects models described the average trajectories for each patient-reported outcome measure after discontinuation and in those who restarted TKI. Of 112 patients in TFR at 12 months, 103 (92.0%) had a 3-point or greater improvement in social function, 80 (71.4%) in social isolation, 11 (9.8%) in satisfaction with sex life, 4 (3.6%) in physical function, and no patients had a 3-point or greater improvement in cognitive function or interest in sexual activity. Patients' scores worsened after restarting TKI. This novel information on functional outcomes in TFR can help guide patient and clinician decision making.",

author = "Schoenbeck, {Kelly L.} and Ehab Atallah and Li Lin and Weinfurt, {Kevin P.} and Jorge Cortes and Deininger, {Michael W.N.} and Vamsi Kota and Larson, {Richard A.} and Mauro, {Michael J.} and Oehler, {Vivian G.} and Javier Pinilla-Ibarz and Radich, {Jerald P.} and Schiffer, {Charles A.} and Shah, {Neil P.} and Silver, {Richard T.} and Thompson, {James E.} and Flynn, {Kathryn E.}",

year = "2022",

month = jan,

day = "1",

doi = "10.1093/jnci/djab184",

language = "English (US)",

volume = "114",

pages = "160--164",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors

AU - Schoenbeck, Kelly L.

AU - Atallah, Ehab

AU - Lin, Li

AU - Weinfurt, Kevin P.

AU - Cortes, Jorge

AU - Deininger, Michael W.N.

AU - Kota, Vamsi

AU - Larson, Richard A.

AU - Mauro, Michael J.

AU - Oehler, Vivian G.

AU - Pinilla-Ibarz, Javier

AU - Radich, Jerald P.

AU - Schiffer, Charles A.

AU - Shah, Neil P.

AU - Silver, Richard T.

AU - Thompson, James E.

AU - Flynn, Kathryn E.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Treatment-free remission (TFR) is a goal for patients with chronic myeloid leukemia (CML). Functional outcomes after discontinuing tyrosine kinase inhibitor (TKI) treatment have not been described. Patient-Reported Outcomes Measurement Information System (PROMIS) measures of social, physical, cognitive, and sexual function were assessed over 36 months in 172 adult patients with chronic phase CML from 14 sites at baseline (on TKI) and after discontinuation. Linear mixed-effects models described the average trajectories for each patient-reported outcome measure after discontinuation and in those who restarted TKI. Of 112 patients in TFR at 12 months, 103 (92.0%) had a 3-point or greater improvement in social function, 80 (71.4%) in social isolation, 11 (9.8%) in satisfaction with sex life, 4 (3.6%) in physical function, and no patients had a 3-point or greater improvement in cognitive function or interest in sexual activity. Patients' scores worsened after restarting TKI. This novel information on functional outcomes in TFR can help guide patient and clinician decision making.

AB - Treatment-free remission (TFR) is a goal for patients with chronic myeloid leukemia (CML). Functional outcomes after discontinuing tyrosine kinase inhibitor (TKI) treatment have not been described. Patient-Reported Outcomes Measurement Information System (PROMIS) measures of social, physical, cognitive, and sexual function were assessed over 36 months in 172 adult patients with chronic phase CML from 14 sites at baseline (on TKI) and after discontinuation. Linear mixed-effects models described the average trajectories for each patient-reported outcome measure after discontinuation and in those who restarted TKI. Of 112 patients in TFR at 12 months, 103 (92.0%) had a 3-point or greater improvement in social function, 80 (71.4%) in social isolation, 11 (9.8%) in satisfaction with sex life, 4 (3.6%) in physical function, and no patients had a 3-point or greater improvement in cognitive function or interest in sexual activity. Patients' scores worsened after restarting TKI. This novel information on functional outcomes in TFR can help guide patient and clinician decision making.

UR - http://www.scopus.com/inward/record.url?scp=85123645552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123645552&partnerID=8YFLogxK

U2 - 10.1093/jnci/djab184

DO - 10.1093/jnci/djab184

M3 - Article

C2 - 34491344

AN - SCOPUS:85123645552

SN - 0027-8874

VL - 114

SP - 160

EP - 164

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 1

ER -

Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this